Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biocryst Pharmaceuticals Inc (BCRX)  
$6.17 0.06 (0.96%) as of 4:30 Fri 6/14


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 189,490,000
Market Cap: 1.17(B)
Last Volume: 2,941,111 Avg Vol: 4,440,946
52 Week Range: $4.13 - $7.98
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    : 16.9
Insider 6 Months    : 16.9
Insider 3/6 Months : 32.4
Guru Rank Number :  455
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 183,601 183,601 183,601 183,601
Total Buy Value $1,048,338 $1,048,338 $1,048,338 $1,048,338
Total People Bought 10 10 10 10
Total Buy Transactions 10 10 10 10
Total Shares Sold 0 0 0 495,199
Total Sell Value $0 $0 $0 $5,999,241
Total People Sold 0 0 0 9
Total Sell Transactions 0 0 0 14
End Date 2024-03-17 2023-12-15 2023-06-16 2022-06-16

   
Records found: 753
  Page 14 of 31  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2018-01-20 4 D $5.59 $22,243 D/D (3,979) 137,383     -
   Stonehouse Jon P President & CEO   •       •      –    2018-01-20 4 D $5.59 $53,575 D/D (9,584) 638,367     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2018-01-20 4 D $5.59 $10,962 D/D (1,961) 77,129     -
   Sheridan William P Senior VP - CMO   •       •      –    2018-01-20 4 D $5.59 $25,871 D/D (4,628) 18,058     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2018-01-01 4 D $4.91 $4,183 D/D (852) 141,362     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2018-01-01 4 D $4.91 $4,115 D/D (838) 103,868     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2018-01-01 4 D $4.91 $2,254 D/D (459) 79,090     -
   Stonehouse Jon P President & CEO   •       •      –    2018-01-01 4 D $4.91 $13,336 D/D (2,716) 647,951     -
   Sheridan William P Senior VP - CMO   •       •      –    2018-01-01 4 D $4.91 $5,740 D/D (1,169) 22,686     -
   Hutson Nancy J Director   •       •      –    2017-12-01 4 A $5.08 $9,997 D/D 1,968 36,135     -
   Ingram Robert Alexander Director   •       •      –    2017-12-01 4 A $5.08 $18,745 D/D 3,690 15,130     -
   Sheridan William P Senior VP - CMO   •       •      –    2017-11-13 4 AS $4.72 $303,543 D/D (64,310) 23,855     -
   Cohen Fred E Director   •       •      –    2017-09-18 4 S $5.42 $294,035 D/D (54,250) 119,410     -
   Cohen Fred E Director   •       •      –    2017-09-18 4 OE $4.27 $231,648 D/D 54,250 173,660     -
   Ingram Robert Alexander Director   •       •      –    2017-09-01 4 A $5.10 $18,748 D/D 3,676 11,440     -
   Hutson Nancy J Director   •       •      –    2017-09-01 4 A $5.10 $9,996 D/D 1,960 34,167     -
   Cohen Fred E Director   •       •      –    2017-06-01 4 A $5.15 $9,996 D/D 1,941 119,410     -
   Hutson Nancy J Director   •       •      –    2017-06-01 4 A $5.15 $9,996 D/D 1,941 32,207     -
   Ingram Robert Alexander Director   •       •      –    2017-06-01 4 A $5.15 $9,996 D/D 1,941 7,764     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-05-22 4 D $5.24 $36,659 D/D (6,996) 142,214     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-05-22 4 OE $4.73 $36,658 D/D 7,750 149,210     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-20 4 AS $9.20 $29,900 D/D (3,250) 141,460     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-20 4 OE $3.78 $12,285 D/D 3,250 144,710     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-16 4 D $8.80 $108,310 D/D (12,308) 141,460     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-16 4 OE $1.42 $108,300 D/D 36,455 153,768     -

  753 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 14 of 31
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed